급성 세균성 피부 및 피부 구조 감염증 시장 : 세계 예측(2026-2032년)

The Acute Bacterial Skin & Skin Structure Infection Market is projected to grow by USD 4.79 billion at a CAGR of 6.41% by 2032.

Acute bacterial skin and skin structure infection (ABSSSI) remains a high-priority infectious disease area because it spans common and potentially severe presentations, including cellulitis, erysipelas, wound infection, and major cutaneous abscesses. These infections place sustained pressure on emergency departments, outpatient clinics, surgical services, and antimicrobial stewardship programs, particularly when methicillin-resistant Staphylococcus aureus (MRSA), beta-hemolytic streptococci, or polymicrobial wound pathogens are involved. The clinical objective is no longer limited to rapid symptom control; health systems are increasingly focused on early risk stratification, microbiology-guided therapy, reduced hospital exposure, shorter intravenous-to-oral transitions, and prevention of recurrence.

The ABSSSI treatment landscape is shaped by the global burden of antimicrobial resistance, rising diabetes prevalence, aging populations, obesity, post-surgical wound complications, trauma-related infections, and healthcare-associated transmission risks. Guideline-based care emphasizes prompt diagnosis, incision and drainage when indicated, appropriate empiric antibiotic selection, reassessment within defined clinical windows, and de-escalation once microbiological or clinical evidence supports narrower therapy. At the same time, payer and hospital priorities are accelerating adoption of outpatient parenteral antimicrobial therapy, long-acting antibiotic regimens, rapid diagnostics, and care pathways that reduce avoidable admissions without compromising safety.

For stakeholders across pharmaceuticals, diagnostics, healthcare delivery, and public health, ABSSSI is a strategically important therapeutic domain where innovation must align with antimicrobial stewardship, evidence-based prescribing, and measurable clinical outcomes. Search demand around acute bacterial skin infection treatment, ABSSSI antibiotics, MRSA skin infection, cellulitis management, wound infection therapy, and antimicrobial resistance reflects the growing need for reliable, decision-ready intelligence across clinical, regulatory, and commercial audiences.

Transformative Shifts in the ABSSSI Landscape

The ABSSSI landscape is undergoing a fundamental shift from broad inpatient management toward precision-enabled, site-of-care-optimized treatment. Historically, moderate-to-severe skin infections often triggered hospitalization for intravenous antibiotics, particularly when MRSA risk was suspected. Current practice is evolving as clinicians use structured severity assessment, comorbidity screening, and early response criteria to determine whether patients can be managed safely in outpatient or observation settings. This shift is supported by improved wound care protocols, greater use of ambulatory infusion services, and therapies designed to maintain effective exposure while reducing repeated hospital visits.

Antimicrobial resistance is another defining force. Surveillance programs consistently identify Staphylococcus aureus, including MRSA, and Streptococcus pyogenes as core pathogens in ABSSSI, while diabetic foot infections, surgical site infections, and traumatic wounds may involve gram-negative and anaerobic organisms. This pathogen diversity has strengthened the role of local antibiograms, culture-based confirmation in purulent or complicated infections, and stewardship interventions that discourage unnecessary broad-spectrum use. Regulatory and clinical trial frameworks have also become more standardized, with early clinical response endpoints and lesion-size assessments used to evaluate therapeutic benefit in ABSSSI studies.

Patient expectations and health system economics are also reshaping care. Convenience, adherence, fewer treatment failures, and reduced readmission risk are increasingly important differentiators. Digital follow-up, home-based wound monitoring, and multidisciplinary care models involving infectious disease specialists, surgeons, pharmacists, diabetes teams, and nursing services are becoming more relevant. Together, these changes are transforming ABSSSI from a relatively protocol-driven antibiotic category into an integrated care pathway focused on diagnosis, treatment optimization, resistance containment, and patient-centered delivery.

Cumulative Impact of Artificial Intelligence on ABSSSI Care

Artificial intelligence is beginning to influence ABSSSI care across diagnosis, triage, treatment selection, operational efficiency, and surveillance. In clinical settings, AI-enabled image analysis has the potential to support assessment of erythema progression, wound dimensions, necrosis, drainage, and healing trajectory using standardized photographic documentation. While clinician evaluation remains essential, algorithm-assisted wound and skin assessment can improve consistency, especially in telemedicine, emergency triage, remote patient monitoring, and post-discharge follow-up.

AI can also strengthen antimicrobial stewardship by integrating electronic health record data, local resistance patterns, allergy history, renal function, prior antibiotic exposure, microbiology results, and comorbidity profiles to support more appropriate empiric therapy and earlier de-escalation. Predictive analytics may help identify patients at higher risk of treatment failure, abscess recurrence, sepsis, hospitalization, or readmission. These use cases are particularly relevant in ABSSSI because early clinical response is a critical marker of treatment success and delayed escalation can worsen outcomes.

At the system level, AI can enhance syndromic surveillance by detecting clusters of skin and soft tissue infections, monitoring MRSA trends, and identifying unusual resistance signals. Natural language processing can extract clinical features from unstructured notes, improving real-world evidence generation on cellulitis, abscesses, wound infections, and antibiotic utilization. However, the cumulative impact of AI will depend on validated datasets, bias mitigation across skin tones and populations, integration into clinician workflows, cybersecurity safeguards, and transparent governance. In ABSSSI, the most valuable AI applications are likely to be those that improve diagnostic confidence, reduce unnecessary antibiotic exposure, and enable safer outpatient management.

Key Regional Insights for ABSSSI

Asia-Pacific is a critical region for ABSSSI due to large population density, high outpatient volumes, variable access to microbiology testing, and the substantial burden of diabetes and trauma-related wound infections. Countries with advanced healthcare systems, including Japan, South Korea, and Australia, emphasize antimicrobial stewardship, hospital infection control, and evidence-based use of anti-MRSA therapies, while emerging economies continue to prioritize access, affordability, and improved primary care diagnosis. In many Asia-Pacific settings, antimicrobial resistance surveillance is expanding through national action plans and regional laboratory networks, but disparities in laboratory capacity influence the speed of pathogen-directed treatment and antibiotic de-escalation.

Europe demonstrates a guideline-driven approach shaped by national antimicrobial resistance action plans, hospital stewardship committees, and coordinated surveillance. Western European countries generally maintain strong diagnostic and prescribing governance, while regional variations remain in access to specialized wound care, outpatient infusion services, and rapid microbiology. North America is characterized by mature infectious disease guidelines, strong stewardship infrastructure, high awareness of community-associated MRSA, and established use of outpatient parenteral antimicrobial therapy for eligible ABSSSI patients. The United States and Canada have advanced emergency care pathways and increasing emphasis on avoiding unnecessary hospital admissions through observation units, long-acting antibiotic approaches, and post-discharge monitoring.

Latin America faces a mixed care environment where urban tertiary centers may have robust infectious disease expertise, while resource variability affects diagnostic access, wound care consistency, and antibiotic stewardship implementation. Brazil and Mexico are important contributors to regional ABSSSI demand due to large patient populations, diabetes prevalence, and urban healthcare utilization. Africa faces the most pronounced diagnostic and access challenges, with ABSSSI management influenced by trauma, limited microbiology infrastructure in some areas, availability of quality-assured antibiotics, and the need for strengthened antimicrobial resistance surveillance. The Middle East is experiencing rising attention to ABSSSI management as diabetes, surgical procedures, and healthcare infrastructure expansion increase the need for coordinated wound infection care; GCC countries are investing in advanced hospital systems and infection control, while broader regional access varies.

Key Group Insights for ABSSSI

NATO countries, while not a healthcare bloc, include many advanced health systems where military medicine, trauma care, field infection control, and readiness planning intersect with ABSSSI management. Lessons from combat wound infection protocols, antimicrobial supply resilience, infection prevention logistics, and mass-casualty readiness can inform broader preparedness for complex skin and soft tissue infections. G7 countries generally lead in clinical research capacity, regulatory standardization, pharmacovigilance, antimicrobial stewardship, and access to advanced diagnostics and therapeutics. Their ABSSSI strategies increasingly emphasize value-based care, outpatient treatment models, real-world evidence on antibiotic effectiveness and safety, and responsible use of broad-spectrum agents.

BRICS countries represent a highly heterogeneous ABSSSI landscape, combining large patient bases, rising chronic disease burdens, substantial surgical and trauma care needs, and varying levels of diagnostic infrastructure. China, India, Brazil, Russia, and South Africa each face distinct resistance and access challenges, making locally adapted treatment pathways, quality-assured antibiotics, and surveillance essential. The European Union provides one of the most structured environments for ABSSSI policy alignment, with antimicrobial resistance surveillance, prescribing stewardship, and regulatory harmonization supporting consistent clinical practice across member states. EU priorities include reducing inappropriate antibiotic use, strengthening cross-border resistance monitoring, and integrating stewardship into hospital accreditation and quality systems.

Within ASEAN, ABSSSI management is shaped by diverse healthcare capacity, tropical climate-related skin infection risks, high patient volumes, and increasing antimicrobial resistance monitoring. Countries with stronger tertiary networks are improving stewardship and wound care protocols, while rural and lower-resource settings continue to face challenges in timely diagnosis, culture access, and continuity of care. The GCC shows growing focus on ABSSSI due to high diabetes prevalence, advanced hospital investment, and demand for effective management of complicated wound infections. Standardized infection prevention, specialist-led antibiotic protocols, outpatient care expansion, and rapid adoption of digital health tools are increasingly relevant across GCC health systems.

Key Country Insights for ABSSSI

China's ABSSSI environment is shaped by large healthcare volumes, expanding stewardship policies, and continued investment in hospital infection control and diagnostics. The United States has a highly developed ABSSSI care environment shaped by community-associated MRSA awareness, emergency department treatment pathways, outpatient parenteral antimicrobial therapy, and strong stewardship expectations. Japan has a mature clinical system with strong regulatory oversight, aging-related skin and wound care needs, and careful antimicrobial governance. India faces high ABSSSI burden due to population scale, diabetes prevalence, trauma exposure, and antimicrobial resistance concerns, making improved diagnostic access and rational antibiotic use central priorities.

Germany benefits from advanced hospital infrastructure, specialist care, and structured surveillance, while the United Kingdom applies strong antimicrobial stewardship principles through national guidance, primary care prescribing governance, and hospital infection control programs. Australia combines high stewardship standards with outpatient care models and public health attention to skin infections in remote and Indigenous communities. France emphasizes antibiotic stewardship and public health campaigns to reduce unnecessary antibiotic use, while South Korea demonstrates advanced hospital capacity, digital health adoption, and strong infection control systems that support rapid diagnosis and standardized management of complicated skin infections.

Italy and Spain face significant burdens related to aging populations, diabetes, surgical site infections, and hospital resource optimization, reinforcing the importance of outpatient management and careful antibiotic selection. Canada emphasizes evidence-based prescribing, infection prevention, and coordinated outpatient care, with regional differences in access across provinces and remote communities. Russia presents a complex landscape where large geography, variable regional infrastructure, and resistance surveillance needs influence ABSSSI care delivery. Brazil's large population, trauma burden, and chronic disease prevalence make wound infection management and stewardship especially important, while Mexico faces substantial ABSSSI demand linked to diabetes, urban healthcare utilization, and variable access to microbiology-guided therapy.

Actionable Recommendations for ABSSSI Industry Leaders

Industry leaders should prioritize ABSSSI strategies that align clinical innovation with antimicrobial stewardship and real-world care delivery. Therapeutic development should focus on clear differentiation in pathogen coverage, safety, dosing convenience, tissue penetration, adherence support, and compatibility with outpatient treatment models. Because unnecessary broad-spectrum exposure contributes to resistance, antibiotic positioning must be supported by robust evidence, microbiological rationale, and guidance on patient selection.

Diagnostic and digital health stakeholders should invest in tools that shorten time to appropriate therapy, improve wound assessment consistency, and support follow-up outside the hospital. Rapid pathogen identification, resistance detection, AI-assisted lesion tracking, and integrated clinical decision support can help reduce treatment failure and avoidable admissions when validated in diverse patient populations. Healthcare providers should expand multidisciplinary ABSSSI pathways that combine emergency medicine, infectious disease, surgery, pharmacy, nursing, and wound care expertise.

Commercial and policy leaders should strengthen education around cellulitis mimics, abscess drainage, diabetic wound infection, MRSA risk assessment, and antibiotic de-escalation. Regional strategies must account for differences in resistance patterns, reimbursement structures, outpatient infusion capacity, and microbiology infrastructure. The most resilient ABSSSI programs will be those that combine access to effective therapy, evidence-based stewardship, patient adherence support, and measurable outcomes such as early clinical response, reduced recurrence, fewer readmissions, and improved wound healing.

Research Methodology

This executive summary is developed through a structured secondary research approach using verified clinical, regulatory, epidemiological, and public health sources. The analysis synthesizes evidence from infectious disease treatment guidelines, antimicrobial resistance surveillance programs, regulatory guidance on ABSSSI clinical trials, peer-reviewed literature, hospital stewardship frameworks, and public health data related to diabetes, wound infections, MRSA, cellulitis, abscess management, and outpatient antibiotic care.

The methodology emphasizes qualitative interpretation rather than market sizing or forecasting. Source evaluation focuses on credibility, recency, clinical relevance, geographic applicability, and consistency across recognized healthcare authorities. Regional, group, and country insights are assessed through healthcare infrastructure indicators, antimicrobial stewardship maturity, diagnostic access, resistance monitoring, chronic disease burden, and care delivery models. Special attention is given to differences between uncomplicated cellulitis, purulent abscesses, surgical site infections, diabetic wound infections, and complicated skin and soft tissue infections.

Analytical outputs are organized to support strategic decision-making for pharmaceutical, diagnostic, healthcare provider, payer, and policy stakeholders. Key themes are validated through triangulation across clinical guidelines, surveillance findings, and real-world care trends. The research intentionally excludes market estimates, market share calculations, and revenue forecasts, focusing instead on evidence-backed drivers, care pathway evolution, regional dynamics, technology impact, and actionable implications for ABSSSI management.

Conclusion

Acute bacterial skin and skin structure infection is evolving from a conventional antibiotic treatment category into a multidisciplinary, technology-enabled, stewardship-driven care priority. Rising antimicrobial resistance, persistent MRSA risk, diabetes-related wound complications, aging populations, and pressure to reduce avoidable hospitalization are reshaping how clinicians diagnose, triage, and treat ABSSSI. The strongest advances are emerging where effective antimicrobial therapy is paired with rapid diagnostics, wound care excellence, outpatient treatment infrastructure, and structured follow-up.

Regional differences remain substantial. Advanced health systems are refining outpatient and digital care models, while emerging and resource-constrained settings continue to prioritize diagnostic capacity, antibiotic quality, surveillance, and equitable access. AI and data-driven tools can improve ABSSSI outcomes when they are clinically validated, integrated into workflows, and aligned with stewardship goals. For industry leaders, the path forward requires evidence-based innovation, responsible antibiotic positioning, and care models that improve early clinical response while limiting resistance pressure.

The future of ABSSSI management will be defined by precision in diagnosis, appropriateness in therapy, efficiency in care delivery, and accountability in outcomes. Stakeholders that address these priorities will be better positioned to support clinicians, improve patient outcomes, and contribute to global efforts against antimicrobial resistance.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Acute Bacterial Skin & Skin Structure Infection Market, by End User

• 7.1. Introduction
• 7.2. Ambulatory Surgical Centers
• 7.3. Home Healthcare Settings
• 7.4. Hospitals

8. Acute Bacterial Skin & Skin Structure Infection Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Offline
• 8.3. Online

9. Acute Bacterial Skin & Skin Structure Infection Market, by Infection Type

• 9.1. Introduction
• 9.2. Cellulitis
• 9.3. Wound Infections
• 9.4. Major Cutaneous Abscesses
• 9.5. Infected Ulcers

10. Acute Bacterial Skin & Skin Structure Infection Market, by Causative Pathogen

• 10.1. Introduction
• 10.2. Gram-Positive
• 10.3. Gram-Negative
• 10.4. Mixed

11. Acute Bacterial Skin & Skin Structure Infection Market, by Drug Class

• 11.1. Introduction
• 11.2. Glycopeptide Antibiotics
• 11.3. Lipoglycopeptide Antibiotics
• 11.4. Oxazolidinones
• 11.5. Lipopeptides

12. Acute Bacterial Skin & Skin Structure Infection Market, by Route of Administration

• 12.1. Introduction
• 12.2. Intravenous (IV) Therapy
• 12.3. Oral Therapy
• 12.4. Sequential IV-to-Oral Therapy

13. Acute Bacterial Skin & Skin Structure Infection Market, by Region

• 13.1. Asia-Pacific
• 13.2. Europe
• 13.3. North America
• 13.4. Latin America
• 13.5. Africa
• 13.6. Middle East

14. Acute Bacterial Skin & Skin Structure Infection Market, by Group

• 14.1. NATO
• 14.2. G7
• 14.3. BRICS
• 14.4. European Union
• 14.5. ASEAN
• 14.6. GCC

15. Acute Bacterial Skin & Skin Structure Infection Market, by Country

• 15.1. China
• 15.2. United States
• 15.3. Japan
• 15.4. India
• 15.5. Germany
• 15.6. United Kingdom
• 15.7. Australia
• 15.8. France
• 15.9. South Korea
• 15.10. Italy
• 15.11. Canada
• 15.12. Russia
• 15.13. Brazil
• 15.14. Mexico
• 15.15. Spain

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. FPNV Positioning Matrix, 2025
• 16.3. Market Concentration Analysis, 2025
  • 16.3.1. Concentration Ratio (CR)
  • 16.3.2. Herfindahl Hirschman Index (HHI)
• 16.4. Recent Developments & Impact Analysis, 2025
• 16.5. Product Portfolio Analysis, 2025
• 16.6. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. AbbVie Inc.
• 17.2. Advanz Pharma Corp. Limited
• 17.3. Almirall, S.A.
• 17.4. Astellas Pharma Inc.
• 17.5. Basilea Pharmaceutica Ltd.
• 17.6. Bayer Aktiengesellschaft
• 17.7. Cumberland Pharmaceuticals Inc.
• 17.8. Dr. Reddy's Laboratories Limited
• 17.9. Fresenius Kabi AG
• 17.10. GlaxoSmithKline plc
• 17.11. Hikma Pharmaceuticals PLC
• 17.12. Iterum Therapeutics plc
• 17.13. Lupin Limited
• 17.14. Melinta Therapeutics, LLC
• 17.15. Merck KGaA
• 17.16. Nabriva Therapeutics plc
• 17.17. Paratek Pharmaceuticals, Inc.
• 17.18. Sandoz Group AG
• 17.19. Shionogi & Co., Ltd.
• 17.20. Spero Therapeutics, Inc.
• 17.21. Sun Pharmaceutical Industries Limited
• 17.22. Teva Pharmaceutical Industries Limited
• 17.23. Venatorx Pharmaceuticals, Inc.
• 17.24. Viatris Inc.
• 17.25. Xellia Pharmaceuticals ApS